PI3K抑制剂在淋巴瘤治疗中的现状和挑战  

PI3K inhibitors in the treatment of lymphoma:present and challenges

作　　者：付瑛 王华庆[1] Fu Ying;Wang Huaqing(Department of Oncology,Tianjin Union Medical Center,Institute of Translational Medicine,Tianjin Union Medical Center,Nankai University,Tianjin Integrative Traditional Chinese and Western Medicine Oncology Institute,Tianjin 300121,China)

机构地区：[1]天津市人民医院肿瘤诊疗中心,南开大学人民医院转化医学研究院,天津市中西医结合肿瘤研究所,天津300121

出　　处：《国际肿瘤学杂志》2024年第10期660-666,共7页Journal of International Oncology

基　　金：国家自然科学基金(82070206);天津市重点学科项目(TJYXZDXK-053B)。

摘　　要：磷脂酰肌醇3-激酶(PI3K)信号通路异常活化是恶性淋巴瘤发病机制之一,PI3K抑制剂是近年来淋巴瘤治疗的新靶点,目前已开发出多种不同类型的PI3K抑制剂,部分药物已经上市,部分药物仍处于临床试验阶段。PI3K抑制剂存在多种不良反应,提高安全性和有效性是PI3K抑制剂未来研发的重要方向。Abnormal activation of phosphoinositide 3-kinase(PI3K)pathway is one of the pathogenesis of malignant lymphoma.PI3K inhibitors are new targets for lymphoma treatment in recent years.At present,a variety of different types of PI3K inhibitors have been developed,some of which have been approved for clinical use,and some are still in clinical trials.PI3K inhibitors have multiple side effects.Improving safety and efficacy is an important direction for the future development of PI3K inhibitors.

关 键 词：磷酸肌醇3-激酶类 淋巴瘤 药物相关性副作用和不良反应 抑制剂 

分 类 号：R733.1[医药卫生—肿瘤]